WWTR1 and chronic myelogenous leukemia, BCR-ABL1 positive: A 2018 study evaluating Hippo signalling pathway gene expression revealed that TAZ is deregulated in patients with chronic myeloid leukaemia (CML) who are refractory to the tyrosine kinase inhibitor (TKI) imatinib [177].